Partnership with Catalent and The Medical House

Partnership for commercialization of adrenaline autoinjector in Europe

Stallergenes S.A. today announced that they have entered into an exclusive agreement with Catalent for the promotion and distribution in Europe of adrenaline autoinjector, ADREFLEX^®, co-developed and co-manufactured by Catalent and The Medical House PLC.

ADREFLEX^® consists of a syringe pre-filled with adrenaline, which will be available for adult and paediatric use (0.3 and 0.15 mg), in an autoinjector device. The Medical House has designed this totally new device to improve the safety and the ease-of-use for patients.

The adrenaline autoinjector is designed for the emergency treatment of anaphylactic shock, mostly due to hymenoptera venom or food allergies, and for use by the patient himself or a relative in the event of an emergency.

Catalent expects to submit the file of ADREFLEX^® dossier for registration in Europe in 2009. Upon approval, Stallergenes will then promote and distribute the product on an exclusive basis in 13 European countries, including the five main markets (UK, France, Germany, Italy, and Spain).

“This agreement with Catalent and The Medical House fits in perfectly with our product portfolio offered to allergy specialists and with our philosophy regarding state-of-the-art in-licensed complementary products,” said Albert Saporta, Chairman and CEO of Stallergenes. “We expect the European market to double in size in the coming years. Furthermore, this agreement represents a unique opportunity for Stallergenes to set up its own commercial operation in the United Kingdom in the near future.  This market accounts for 50% of the adrenaline European market.”

The terms of the agreement are undisclosed.